We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App





Eurofins Clinical Diagnostics Launches Lower Cost Highly Accurate COVID-19 PCR Test

By LabMedica International staff writers
Posted on 06 Aug 2020
Eurofins U.S. More...
Clinical Diagnostics (Luxembourg) has launched its pooled PCR test to detect SARS-CoV-2 and significantly reduce the price per PCR test for clients.

Along with sentinel assays, pooled testing will be another integral tool in Eurofins’ comprehensive SARS-CoV-2 SAFER@WORK program. The test will be offered through its network of US laboratories, including Viracor Eurofins beginning mid-August. Pooling can be used to continuously and cost-effectively monitor prescreened, low-risk groups that show a low prevalence of COVID-19 infection. It can also be used as part of surveillance testing for positive individuals in quarantine. Due to the strong sensitivity of the Eurofins’ RT-PCR assay, pooling represents a highly accurate method with very high sensitivity and excellent specificity.

In pooled testing, Eurofins will pool five specimens and then test a single PCR assay while retaining the original, individual samples. Results are typically provided within 24-48 hours. If SARS-CoV-2 is detected in the pool, individual PCR tests will be performed to definitively identify the individual sample(s) that were positive. If there is no virus detected in the pool, no further testing is required.

Related Links:
Eurofins U.S. Clinical Diagnostics


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Plasmodium Test
Plasmodium DNA Real Time PCR Kit
New
Uric Acid Meter
PA-16
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Pathology

view channel
Image: Microscopy image of invasive breast cancer cells degrading their underlying extracellular matrix (Photo courtesy of University of Turku)

Visualization Tool Illuminates Breast Cancer Cell Migration to Suggest New Treatment Avenues

Patients with breast cancer who progress from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) face a significantly worse prognosis, as metastatic disease remains incurable.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.